AstraZeneca (LON:AZN) projected continued revenue and earnings growth in 2026 on Tuesday, while its results for the fourth quarter came in line with expectations.

Read More »

Is There An Opportunity With AstraZeneca PLC's (LON:AZN) 46% Undervaluation?

In this article we are going to estimate the intrinsic value of AstraZeneca PLC (LON:AZN) by projecting its future cash flows and then discounting them to today's value. One way to achieve this is by ...

Read More »

AstraZeneca's (LON:AZN) investors will be pleased with their notable 61% return over the last five years

The main point of investing for the long term is to make money. But more than that, you probably want to see it rise more than the market average. But AstraZeneca PLC (LON:AZN) has fallen short of ...

Read More »

EU panel backs Enhertu for certain breast cancers

LONDON - AstraZeneca PLC (LON:AZN) and Daiichi Sankyo's Enhertu has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

Read More »

AstraZeneca's (LON:AZN) investors will be pleased with their respectable 55% return over the last five years

AstraZeneca PLC (LON:AZN) shareholders might be concerned after seeing the share price drop 11% in the last quarter. On the bright side the returns have been quite good over the last half decade.

Read More »